- Home
- ALXO vs INCR Comparison
ALXO vs INCR Comparison
Compare ALXO & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- INCR
- Stock Information
- Founded
- ALXO 2015
- INCR 1994
- Country
- ALXO United States
- INCR Israel
- Employees
- ALXO N/A
- INCR N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- INCR Biotechnology: Pharmaceutical Preparations
- Sector
- ALXO Health Care
- INCR Health Care
- Exchange
- ALXO Nasdaq
- INCR Nasdaq
- Market Cap
- ALXO 76.5M
- INCR 76.7M
- IPO Year
- ALXO 2020
- INCR N/A
- Fundamental
- Price
- ALXO $0.66
- INCR $1.41
- Analyst Decision
- ALXO Strong Buy
- INCR
- Analyst Count
- ALXO 6
- INCR 0
- Target Price
- ALXO $4.14
- INCR N/A
- AVG Volume (30 Days)
- ALXO 1.4M
- INCR 15.9K
- Earning Date
- ALXO 03-06-2025
- INCR 04-08-2025
- Dividend Yield
- ALXO N/A
- INCR N/A
- EPS Growth
- ALXO N/A
- INCR N/A
- EPS
- ALXO N/A
- INCR N/A
- Revenue
- ALXO N/A
- INCR $72,420,918.00
- Revenue This Year
- ALXO N/A
- INCR N/A
- Revenue Next Year
- ALXO N/A
- INCR $39.30
- P/E Ratio
- ALXO N/A
- INCR N/A
- Revenue Growth
- ALXO N/A
- INCR N/A
- 52 Week Low
- ALXO $0.65
- INCR $1.17
- 52 Week High
- ALXO $17.83
- INCR $3.72
- Technical
- Relative Strength Index (RSI)
- ALXO 33.23
- INCR 31.26
- Support Level
- ALXO $0.65
- INCR $1.37
- Resistance Level
- ALXO $0.74
- INCR $1.48
- Average True Range (ATR)
- ALXO 0.07
- INCR 0.06
- MACD
- ALXO -0.00
- INCR -0.01
- Stochastic Oscillator
- ALXO 0.54
- INCR 15.94
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.